ClinicalTrials.gg
CompletedNCT06128174LS-PersAFoneUpdated Feb 11, 2026

LS-PersAFone: Pulsed Field Ablation for Long-Standing Persistent Atrial Fibrillation

An interventional study of Farawave PFA catheter in Long-standing Persistent AF, sponsored by Vivek Reddy. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Vivek Reddy · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Atrial Fibrillation by Vivek Reddy — 1 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · Vivek Reddy.

Enrollment
11th of 13
20 · median 88
Started
2024
the only one that year
No phase
12 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Atrial Fibrillation by Vivek Reddy, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 12 with no phase, and was the 12th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

1 of the 14 studies in Atrial Fibrillation by Vivek Reddy is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Atrial Fibrillation by Vivek Reddy, or all of them as a file.
02

Study summary

This is a prospective, single-arm trial. The objective of the study is to determine the rate of atrial arrhythmia recurrence after pulmonary vein isolation (PVI) plus posterior wall isolation (PWI) using the Farawave PFA catheter in patients with longstanding persistent atrial fibrillation (AF). The trial will be conducted at as many as 10 US sites. Upon completion of site initiation, enrollment is expected to accrue at a rate of 10 patients per month. Total enrollment is expected to consist of 100 subjects. Accrual is expected to take 18 months, and all patients will be followed for 12 months post randomization.

This study will be completed in 2 phases. There will be a 20 subject pilot phase, enrolled at one site (Mount Sinai). After completion of the pilot phase, the FDA will be provided with acute safety data (1 month). During the FDA's review of the pilot phase, enrollment may continue at the initial site. Also, IRB submissions at other prospective sites (up to a total of 10) may be initiated. Upon receipt of the go-ahead from FDA and after consultation with the study sponsor, the second phase of the study (to enroll 100 total subjects) will be performed. This research study currently has approval to enroll 25 patents. Should FDA grant approval to continue the study, the research team will expand as above and update this posting.

Read the detailed description

Among patients with paroxysmal AF, numerous randomized studies have demonstrated the efficacy of catheter ablation as compared with anti-arrhythmic therapy to prevent arrhythmia recurrence. However, among patients with long-standing persistent AF the efficacy of catheter ablation remains particularly poor, with long-term freedom from Atrial Tachycardia AT/AF off anti-arrhythmic medications generally as low as 30% after one procedure. Multiple catheter ablation procedures are usually required in long-standing persistent AF to achieve arrhythmia suppression.

Although pulmonary vein isolation (PVI) has been the main focus of catheter ablation for atrial fibrillation, as a lesion set it is insufficient for long-standing persistent AF. Electrical isolation of the posterior wall has been proposed as an adjunctive lesion set to PVI for patients with persistent and long-standing persistent AF. The left atrial posterior wall has a common embryological origin with the pulmonary veins, and differences in fiber orientation at the intersection of the pulmonary veins and the LA posterior wall may contribute to localized re-entrant circuits and subsequent AF. In addition, the posterior wall is a site of parasympathetic innervation that could act as a non-pulmonary vein trigger for AF. Typically, posterior wall isolation (PWI) during catheter ablation involves the creation of lines between the superior edge of the left- and right-sided PVI lesion sets, as well as between the inferior edges of the left- and right-sided lesion sets. Another approach involves the delivery of lesions throughout the posterior wall to target any electrical activity.

Observational studies of PWI have suggested that it improves outcomes over PVI in persistent AF. However, randomized trials of catheter ablation for PWI have not shown clinical benefit over PVI. An important possible reason for the negative results of the randomized trials is the difficulty achieving durable PWI. In fact, a recent clinical trial of a hybrid epicardial/endocardial ablation to achieve PVI and PWI was compared with a standard endocardial catheter ablation set of PVI and a roof line. The CONVERGE clinical trial of 153 patients with persistent and long-standing persistent AF showed significantly higher rate of AF burden reduction in the treatment group (74% versus 55%) by 18 months. The durability of PWI through epicardial ablation may be a major reason for the increased efficacy in the hybrid ablation group.

Left atrial posterior wall ablation is also supported by 2 important mechanistic studies-1 surgical (HISTORIC-AF) and 1 catheter based (PersAFone). Like in CONVERGE, HISTORIC-AF evaluated a 2-procedure strategy of a minimally invasive, thoracoscopic epicardial RF tool to create a posterior box lesion isolating all PVs and the posterior wall en bloc; followed 1 month later by catheter-based endocardial touch-up ablation of residual conduction gaps. This multicenter, prospective, nonrandomized study of 100 patients (32% with PerAF, 68% with longstanding PerAF) used implantable loop recorders (ILRs) for continuous ECG monitoring for AF recurrence, and nonetheless demonstrated an excellent 1-year maintenance of sinus rhythm rate of 88%. In PersAFone, patients with PerAF underwent PVI + PWI using the Farawave pulsed field ablation (PFA) catheter. While this trial only included 25 patients, the trial was notable for a design which included remapping at 3 months (demonstrating durable PWI in all patients) with any necessary touch-up ablation performed. Following this, the one-year freedom from AF recurrence was 92±5.4%.

PFA for AF offers very promising efficacy for PVI, with \~96% durability of isolated veins at 90-day remapping. Furthermore, studies of PFA for PVI have also shown an extremely low risk of esophageal injury.

Together, these data support a PFA-based PVI+PWI strategy as a simple, safe, fast approach to treat this troublesome population of long-standing PerAF patients. Accordingly, the research team proposes a prospective study of PVI and PWI for patients with longstanding PerAF, using PFA in order to minimize the risk of esophageal injury and maximize the likelihood of durable catheter-based ablation lesions. The research team seeks to obtain precise estimates of arrhythmia recurrence post-ablation through ILRs in follow-up.

03

Conditions studied

  • Long-standing Persistent AF

Browse trials for

Keywords

  • Long-standing Persistent AF
  • Persistent Afib greater than 1 year
  • Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Long-standing Persistent AF (>1 year continuous AF)
  • Planned for a first-ever AF ablation procedure
  • >30% (as assessed within 6 months of randomization)

Exclusion criteria

Exclusion Criteria:

  • Prior left atrial ablation or left atrial surgery (including mitral valve surgery)
  • Hypertrophic cardiomyopathy
  • Major cardiac surgery within 6 months preceding the consent date
  • Within 3 months preceding the consent date:

    • Stroke, , intracranial bleeding
    • Any thromboembolic event
    • Carotid stenting or endarterectomy
  • less than one year
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Patients with longstanding persistent atrial fibrillation (AF)

    All subjects will undergo Pulmonary vein isolation (PVI) and Posterior wall isolation (PWI) with the Farapulse catheter.

    Device: Farawave PFA catheter

Interventions

  • DeviceFarawave PFA catheter

    The FARAWAVE Pulsed Field Ablation Catheter (FARAWAVE Catheter) is a flexible tube with electrodes at the end, which is inserted through a blood vessel in your groin. The study doctor will use the FARAWAVE Catheter to deliver the pulsed electrical energy to ablate (destroy) the heart tissue. This process is designed to create a scar in the heart tissue, stopping the unwanted electrical signals that cause the atrial fibrillation.

06

What researchers measure

Primary outcomes

  1. Number of participants with freedom from recurrent atrial arrhythmias

    Number of participants with freedom from recurrent atrial arrhythmias (AF/AT/AFL) (post 3-month blanking), assessed as time to first recurrence. AF/AT/AFL will be defined as an episode of the corresponding arrhythmia that is recorded for review, where the recording contains at least 30 seconds of continuous interpretable signal. An exception is a 12-lead ECG where the arrhythmia occurs during the entire tracing and the continuous interpretable signal is 10 seconds or longer.

    Time frame: post 3 month blanking period till end of study at 12 months

Secondary outcomes

  1. Proportion with post-blanking period AF burden <12% by device interrogation

    Proportion with post-blanking period AF burden \<12% by device interrogation. The overall burden of AF will be assessed in the treatment and control groups, and the proportion of patients in each group with AF burden \<12% will be compared.

    Time frame: end of study at 12 months

07

Study locations

1 site
  • Mount Sinai Hospital
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No — Data not available/not applicable.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Nov 2025, 22 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 22 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Jan 23, 2024
Primary completionActual
Nov 24, 2025
CompletionActual
Dec 8, 2025
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06128174
Lead sponsor
Vivek Reddy
Responsible party
Vivek Reddy (EP Division Director, Professor, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Nov 13, 2023
Start date
Jan 23, 2024
Primary completion
Nov 24, 2025
Completion
Dec 8, 2025
Last update
Feb 11, 2026

Study contacts

Vivek Reddy, MD
principal investigator · Icahn School of Medicine
William Whang, MD
principal investigator · Icahn School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion